Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS-312 open-label safety extension of inhaled liposomal amikacin in refractory MAC lung disease
NL-OMON43501Phase 3Active, not recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jun 2016
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amikacin liposome in Mycobacterium avium lung disease and nontuberculous mycobacterial lung disease, sponsored by Insmed Incorporated. Primary endpoint: Long-term safety and tolerability. Started Jun 2016; status: active, not recruiting.
02
Drugs
amikacin liposome
03
Conditions
Mycobacterium avium lung diseasenontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on NL-OMON43501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43501.